myxoinflammatory fibroblastic sarcoma

myxoinflammatory fibroblastic sarcoma

low-grade malignant tumor of subcutaneous soft tissues invading into the joints and tendons, composed of fibroblastic cells, often showing virallike inclusion in nuclei and large nucleoli, arranged in clusters of myxoid stroma and infiltrates of inflammatory cells.
References in periodicals archive ?
At the end of the last century, several groups described 3 new types of soft tissue tumors with similar clinical presentations: pleomorphic hyalinizing angiectatic tumor of soft parts (PHAT) in 1996,1 myxoinflammatory fibroblastic sarcoma (MIFS) in 1998,2-4 and hemosiderotic fibrolipomatous tumor (HFLT) in 2000.5 These tumors are listed as separate entities in the recently published WHO Classification of Tumors of Soft Tissue and Bone.6 A common recurrent genetic change, t(1;10)(p22;q24) translocation, was detected in a subset of HFLT, MIFS, HFLT/MIFS hybrid, and PHAT.
Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor.
In literature, one case initially misdiagnosed as acral myxoinflammatory fibroblastic sarcoma, turned out to be nodular fasciitis of the tendon sheath.
Myxoinflammatory fibroblastic sarcoma (MIES) is a rare, low-grade, malignant, soft-tissue tumor that typically affects the distal extremities of middle-aged patients.
Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare soft tissue tumor first reported in 1998 by 3 independent investigators.
Myxoinflammatory fibroblastic sarcoma presents as a painless, slowly growing mass.
Lucas, MD, reviews and updates myxoinflammatory fibroblastic sarcoma, a challenging soft tissue tumor that is frequently misdiagnosed by pathologists unaware of its clinicopathologic manifestations.
Myxoinflammatory fibroblastic sarcoma (MIFS) typically affects lower extremities.
Myxoinflammatory Fibroblastic Sarcoma (Also Called Inflammatory Myxohyaline Tumor of Distal Extremities).--Myxoinflammatory fibroblastic sarcoma (MIFS) and superficial [CD34.sup.+] fibroblastic tumor share some morphologic features such as bizarre-appearing nuclei with prominent nucleoli, low mitotic rate, rare cytokeratin expression, and prominent chronic inflammatory cell infiltrate within the tumor.
Consistent t(1; 10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor.
Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare, malignant soft tissue neoplasm that was first described in 1997 by Montgomery, (1) with further nearsimultaneous descriptions the following year by Montgomery et al (2) (51 cases), Meis-Kindblom and Kindblo (m) 3 (44 cases), and Michal4 (5 cases).
Five cases of myxoinflammatory fibroblastic sarcoma were present in the IB group.